Assessment of Cytokine (α-TNF) with Erythropoietin and their Correlation in Pulmonary Tuberculosis with Anaemia

Priti Yadav a#, V. S. S Ramavataram Divvi a† and Tejas Shah a‡

a Department of Biochemistry, Smt. BK Shah Medical Institute and Research Center and Dhiraj General Hospital (DGH), Sumandeep Vidyapeeth (Deemed to be University), Pipera, Vadodara, Gujarat, India.

Authors’ contributions
This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information
DOI: 10.9734/JPRI/2021/v33i52b33592
Editor(s):
(1) Dr. Francisco Cruz-Sosa, Metropolitan Autonomous University Iztapalapa Campus, México.
Reviewers:
(1) Houda Belguendouz, University of Sciences and Technology Houari Boumediene, USTHB, Algeria.
(2) Micheal Vincent Abiodun, Federal Polytechnic Bida Nigeria, Nigeria.
Complete Peer review History, details of the editor(s), Reviewers and additional Reviewers are available here: https://www.sdiarticle5.com/review-history/75971

ABSTRACT

Globally tuberculosis is the 9th leading cause of death worldwide. As pulmonary tuberculosis (PTB) is a chronic disease, anaemia of inflammation due to bacterial burden play a vital role in pathophysiology of anaemia. Inflammation interferes with erythropoietin (EPO) function.

Methods: The present study was an analytical type of case control study. The study included 100 newly diagnosed anaemic PTB cases and 50 newly diagnosed non anaemic PTB controls. The PTB was confirmed by microscopic examination of sputum specimen for the detection of Acid-Fast Bacilli (AFB). Both cases and controls were subjected to hematological analysis by automated cell counter and serum α-TNF and EPO by ELISA method.

Results: Statistically significant difference was observed in levels of both α-TNF and EPO in anemic and non-anemic PTB groups (p<0.001). α-TNF (214.56±82.30) levels were found to be significantly higher in anaemic PTB group while EPO level (58.44 ±14.97) were found to be significantly higher in non anaemic PTB group. Significant inverse correlation (r1=cases,
PTB is known to be associated with complications and anemia is a commonly associated one with major risk factor for mortality [1]. Generally pulmonary tuberculosis is coupled with major abnormality in haemopoiesis [8,14]. In chronic PTB abnormal hemoglobin levels is considered to be multifactorial and attributable to the fundamental chronic inflammation. Decrease red blood cell survival, disturbance in iron metabolism and reduced EPO action have been implicated in the pathogenesis of PTB anemia [15]. In some infectious disease and chronic inflammatory disorders EPO act as anti-inflammatory cytokine [16]. Erythropoietin primarily act as a regulator of erythropoiesis or red blood cell production [16-20]. EPO affect the production of red blood cells by stimulating differentiation and proliferation of erythroid cells in bone marrow [21-24]. Previous studies mentioned EPO activity is affected by cytokine mediated proinflammatory signaling [6].

Inflammation in PTB is mainly due to bacterial burden leading to increased production of proinflammatory cytokines like TNF-α, [25] which is known to contribute to anemia by decreased erythropoietin production, [7,26] suppressed action of bone marrow to erythropoietin and its interference with metabolism of iron [1,25].

Looking into above aspects, the present study was taken up to assess the effect of extent of chronic inflammation on Haemoglobin and Erythropoietin.

2. MATERIALS AND METHODS

The present study was an analytical type of case control study conducted at Smt. BK Shah Medical Institute and Research Center and Dhiraj General Hospital (DGH) Sumandeep Vidyapeeth, Piperia, Vadodara, Gujrat, India from April 2019 to April 2020 year. The study enclosed 150 newly diagnosed PTB subjects which were classified as 100 newly diagnosed anemic PTB cases and age and sex matched 50 newly diagnosed non anemic PTB controls. PTB clinical diagnosis of cases and control was diagnosed by pulmonologist and microscopic examination of sputum for of Acid-Fast Bacilli
(AFB) detection and by CBNAAT (Cartridge based nucleic acid amplification test).

2.1 Patients’ Selection

Newly diagnosed anaemic Pulmonary Tuberculosis subject of either gender having age group of 18-70 years who were sputum smear positive for Acid Fast Bacilli (Z-N staining) and CBNAAT positive with following Hb levels (acc to WHO) [27]: Males: ≤13 g/dL and Females: ≤12 g/dL.

2.2 Exclusion Criteria

The patients with extra-pulmonary TB and/or patients requiring surgical intervention, patients with history of prior anti TB treatment, pregnant women, patients with HIV, patients with chronic kidney disease, heart disease, Cancer or any other inflammatory conditions were excluded from the study.

2.3 Sample Collection and Processing

5 ml blood was collected from each study group individual under all aseptic precautions. Out of which one part of blood (2 ml) was transferred in EDTA vial for CBC count using automated cell counter Nihon Kohden (3-part cell counter) by flow cytometry method. Remaining blood (3 ml) was transferred in plain vial and left to clot for 30 min and then centrifuged at 3000 RPM. Separated serum samples were stored at -20°C in research lab for erythropoietin and α-TNF analysis. The patient confidentiality was maintained at each and every level. Serumα-TNF and EPO were estimated by sandwich ELISA method using commercially available kits according to manufacturer instructions.

2.4 Statistical Analysis

Data were analyzed with the help of software SPSS version 20. The mean values are represented as mean and SD. The statistical difference between cases and control were determined by Student independent sample t-test. Relationship between α-TNF, EPO and Hb were determined by Pearson’s correlation analysis. The p-value <0.05 were considered as statistically significant.

3. RESULTS

In present study 100 newly diagnosed sputum positive anemic PTB subjects with mean age of 42.0±14.5 years (age range 18-70) and 50 newly diagnosed sputum positive anemic PTB controls 42.98±14.21 years (age range 18-70 years) were included. The data of present study was presented in the form of mean and standard deviation (SD) as (Mean ± SD).

Table 1. Comparison between mean of different parameters in PTB cases and controls

| Parameter   | Non-Anemic PTB Control (n=50) (Mean ± SD) | Anemic PTB cases (n=100) (Mean ± SD) | p-value |
|-------------|------------------------------------------|-------------------------------------|---------|
| Hb (g/dl)   | 13.13±0.63                               | 9.78±1.53                           | 0.000*  |
| RBC (millions/μL) | 4.59±0.85                         | 3.95±1.02                           | 0.000*  |
| PCV (%)     | 39.44±2.19                               | 29.70±4.52                          | 0.000*  |
| MCH (Pg/cell) | 27.99±9.99                      | 24.83±3.23                          | 0.005*  |
| MCV (fl)    | 88.17±6.74                               | 80.28±8.57                          | 0.017*  |
| MCHC (g/dl) | 32.24±1.09                               | 29.93±3.13                          | 0.000*  |
| WBC(Cells/cumm) | 9758.00±3115.53              | 11137.70±3171.49                  | 0.013*  |
| Platelets (lakhscells) | 2.38±0.56                     | 2.7818±0.82                        | 0.003*  |
| EPO(mIU/mL) | 58.44 ±14.97                             | 47.28±6.40                          | 0.002*  |
| α-TNF(pg/mL) | 55.32±24.18                           | 214.56±82.30                        | 0.000*  |

*p<0.05 is significant

Table 2. Correlations between the Parameters in anemic PTB cases

| Parameters | α-TNF r value | Hb r value | EPO r-value |
|------------|---------------|------------|-------------|
| α-TNF(pg/mL) | -             | -0.257     | -           |
| Hb(g/dl)   | -.202         | -          | -           |
| EPO(mIU/mL) | -             | 0.106      | -           |

P ≤ 0.05
Fig. 1. Correlation between α-TNF and EPO in anemic PTB group

\[(r = -0.257, p < 0.001)\]

Fig. 2. Correlation between α-TNF and Hb in anemic PTB group

\[(r = -0.202, p < 0.05)\]
Fig. 3. Correlation between EPO and Hb in anemic PTB group

The mean level of Hb, Packed Cell Volume (PCV), RBC, Mean Corpuscular Hemoglobin (MCH) Mean Corpuscular Volume (MCV), and Mean Corpuscular Hemoglobin Concentration (MCHC) were lower in anemic PTB cases compared to non-anemic PTB controls while WBC values and platelets values were higher in anemic PTB case group compared to non-anemic PTB controls group. EPO (47.28±6.40 mIU/mL) was found to be significantly lower in anemic PTB cases and observed higher (58.44±14.97 mIU/mL) in non-anemic PTB controls (p<0.05) as illustrated in [Table 1].

Further, with respect to Hb, Hb was found to be significantly lower in cases as compared to controls as shown in [Table 1].

Pearson correlation's analysis of α-TNF, EPO and Hb were demonstrated in cases with anemic PTB [Table 2]. It was observed that statistically significant inverse correlation between serum α-TNF and Hb level (r=-0.202, p<0.05) in anemic PTB cases [Fig. 2]. A statistically significant inverse correlation was observed between serum levels of TNF-α and EPO (r=-0.257, p<0.05) in PTB cases [Fig.1] Furthermore, we observed statistically insignificant correlation between serum EPO and Hb level (r=0.106, p>0.05) in PTB cases [Fig-3].

4. DISCUSSION

Anemia is one of the most common abnormality seen in TB patients caused by poor nutritional [10] status and increased cytokines levels due to inflammation [11,28]. In this study, we aimed to assess levels of α-TNF and EPO and their correlation in anemic and non-anemic pulmonary tuberculosis with same age matched criteria.

A significantly higher mean levels of α-TNF in anemic PTB (cases) than that of non-anemic PTB (control) and have statistically significant difference (p<0.05) (Table-1). When compared with the study done Kulkarni et al (2015) [8] to demonstrate the levels of α-TNF and reveled that the levels were significantly higher than that of healthy controls. In Bhat H et al. (2018) [2] study also observed a similar pattern. PTB is a chronic disease which is correlated with increased cytokines such as α-TNF, which might be allied with anemia of chronic diseases. It may also be due to increased bacterial burden in case group compared to control group that α-TNF levels are significantly increased in cases [2].
Chronic inflammatory diseases have also been associated with decreased EPO levels due to various mechanisms [29]. Chronic inflammation leads to increased expression of inflammatory cytokines like interleukin (IL-1) and α-TNF [29]. In chronic inflammatory disease like PTB, invading bacteria induces the production of TNF-α together with other inflammatory cytokines during the activation of T-lymphocytes and monocytes [2]. α-TNF inhibits EPO synthesis and interferes with differentiation and proliferation of erythroid progenitor cells [2,30,31]. α-TNF also induces the production of ROS [32,33], which again interferes with EPO producing cells and affecting the binding affinity of EPO inducing transcription factors thus suppressing bone marrow response to EPO [8]. Inverse correlation between TNF-α and EPO observed in this study in case group (p<0.001, Fig-2) can be explained by above reasons. Other authors like Kulkarni RA et al., and Bhat H et al., also observed similar relation between α-TNF with EPO in PTB cases.

We have measured the concentration of EPO and observed a significantly lowered level in anemic PTB (cases) than that of non-anemic PTB (control) respectively and have statistically significant difference (p<0.05) (Table-1). Bhat H et al. (2018) [2], conducted a study on PTB cases and healthy controls and observed significantly increased levels of EPO. When compared with the study done by Kulkarni et al. (2015) [8], has conducted a study on PTB cases and found increased EPO levels than healthy controls. Studies had also shown that in PTB, EPO levels generally increases as compared to healthy controls. As PTB is considered as chronic inflammatory disease, therefore increased EPO levels in both cases and controls can be attributed to chronic inflammation [8,29]. Also lower levels of EPO in case group as compared to control group of this study can be attributed to increased cytokine levels and bacterial burden in these subjects [2]. Bruno CM et al [34], had observed increased EPO levels in anaemic as compared to non anaemic chronic inflammatory disease condition, but they have not explained any mechanism for such an observation.

Hemoglobin levels were taken as grouping variable in this study, hence statistical difference was observed among the groups. Decreased mean Hb levels in anemic PTB group because according to inclusion criteria Hb (males and female cases) and normal mean Hb levels in control group as compared to case group (p<0.001, Table-1) because of non anaemic nature (inclusion criteria of controls) of subjects.

TNF-α along with other cytokines also affects hemoglobin concentration in PTB cases [8]. Hemoglobin concentration is affected by iron concentration. TNF-α meddles with iron metabolism by efficiently withholding Iron from microbes as a protection against invading microbial pathogens and stimulate the iron storage which reduced the iron supply for erythroid cells, leading to decreased hemoglobin concentration [2,9]. The inverse correlation between TNF-α and Hb concentration observed in both the groups (p<0.05, Table-2) in this study can be because of bacterial burden [2], and meddling effect of TNF-α with iron metabolism [9].

EPO is a hormone responsible for erythropoiesis [18]. In normal healthy individuals [35], and iron deficiency anaemia [36], significant negative correlation is present between EPO and Hb concentration. In chronic inflammatory conditions, this correlation is disrupted and neither negative nor positive relation is seen [2,8]. In studies having PTB cases, no significant correlation is observed between the two because of the effect of cytokines and bacterial burden. In conjunction with other studies, present study also observed that there is no significant correlation between EPO and Hb (p<0.05, Fig-3). Thus, in this study we observed the subnormal Hb associated with the severity of cytokine α-TNF and their action of suppression of EPO which might be linked to underlying inflammatory mechanism and caused anemia in PTB.

5. CONCLUSION

The present study shows that anaemic or non anaemic PTB, both are associated with increased α-TNF and decreased EPO and Hb, but the extent of inflammation i.e., α-TNF levels are responsible for the development of anaemia. Thus, we conclude that though anaemia in PTB is a complication, but this complication can be reduced by reducing inflammation rather than focusing on treatment of anaemia, which will further increase the cost of treatment in PTB cases.
6. LIMITATION

Further comprehensive large sample size study would be needed to achieve firm conclusion. Restricted budget (cost of kits) and time, number of PTB subjects were restricted. In this study, we have not done follow-up of anemic and non-anemic PTB patients which could have been more enlightening in evaluating predictive applications of inflammatory cytokine and EPO.

ETHICAL APPROVAL AND CONSENT

The study protocol was approved by Institutional Ethics Committee (SVIEC/ON/MED/PhD/19023). After describing the study in details, the written consent was taken from all the patients before enrolment.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Rohini K, Bhat MS, Srikumar PS, Kumar AM. Assessment of hematological parameters in pulmonary tuberculosis patients. Indian Journal of Clinical Biochemistry. 2016 Jul;31(3):332-5.

2. Bhat H, Ambekar JG, Harwalkar AK, Dongre N, Das KK. Role of TNF-α on the Function of Erythropoietin and Haematological Profile in Pulmonary Tuberculosis Patients. Journal of Clinical & Diagnostic Research. 2018;12(8).

3. Report. Revised national TB control program Annual report; 2019. Available:https://tbcindia.gov.in/WriteReadData/India%20TB%20Report%202019.pdf

4. Kiazyk S, Ball TB. Tuberculosis (TB): Latent tuberculosis infection: An overview. Canada Communicable Disease Report. 2017;43(3-4):62.

5. Barry CE, Bosshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nature Reviews Microbiology. 2009;7(12):845-55.

6. Gluba-Brzózka A, Franczyk B, Olszewski R, Rysz J. The influence of inflammation on anemia in CKD patients. International journal of molecular sciences. 2020 ;21(3):725.

7. Morceau F, Dicato M, Diederich M. Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis. Mediators of inflammation. 2009 Oct;2009.

8. Kulkarni RA, Deshpande AR, Saxena K. Interplay of serum erythropoietin and inflammatory cytokine in anemic tuberculosis patients. National journal of community medicine.2015 Dec.National Journal of Community Medicine. 2015;6(4).

9. Kulkarni R, Deshpande A, Saxena K, Sinha AR, Verma M, Saxena R. Role of Tumor necrosis factor alpha, Malondialdehyde & serum Iron in Anemic Tuberculosis Patients. Biomed Res. 2011;22(1):69-72.

10. Lee SW, Kang YA, Yoon YS, Um SW, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. The prevalence and evolution of anemia associated with tuberculosis. Journal of Korean medical science. 2006;21(6):1028.

11. Bashir BA, Abdallah SA, Mohamedani AA. Anemia among patients with pulmonary tuberculosis in port Sudan, eastern Sudan. International Journal of Recent Scientific Research. 2015;8(5):4128-31.

12. Mukherjee A, Kaushik RM, Sindhwani G, Kaushik R. Prevalence and characteristics of anemia in new cases of pulmonary tuberculosis in a tertiary care hospital in Uttarakhand, India. SRHU Medical Journal. 2017;1(1):10-5.

13. Monjur F, Rizwan F. A cross-sectional study of morphological types of anemia in pulmonary tuberculosis patient and associated risk indicators in a selected hospital of Dhaka city, Bangladesh. Int J Chem Environ Biol Sci 2014;2(4): 215-9.

14. Şahin F, Yazar E, Yıldız P. Prominent features of platelet count, plateletcrit, mean platelet volume and platelet distribution width in pulmonary tuberculosis. Multidisciplinary Respiratory Medicine. 2012 ;7(1):1-7.
15. Ebrahim O, Folb PI, Robson SC, Jacobs P. Blunted erythropoietin response to anaemia in tuberculosis. European Journal of Haematology. 1995;55(4): 251-4.

16. Nairz M, Sonnweber T, Schroll A, Theurl I, Weiss G. The pleiotropic effects of erythropoietin in infection and inflammation. Microbes and infection. 2012;14(3):238-46.

17. El-Korashy RI, Amin YM, Moussa HA, Badawy I, Bakr SM. Study the relationship of erythropoietin and chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis. 2012; 61(3):53-7.

18. Watowich SS. The erythropoietin receptor: molecular structure and hematopoietic signaling pathways. Journal of Investigative Medicine. 2011;59(7): 1067-72.

19. Jelkmann W. Molecular biology of erythropoietin. Internal medicine. 2004;43(8):649-59.

20. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LD, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 1999; 283(5404):987-90.

21. Panjeta M, Tahirowic I, Karamereh J, Sofic E, Ridic O, Coric J. The relation of erythropoietin towards hemoglobin and hematocrit in varying degrees of renal insufficiency. Materia socio-medica. 2015; 27(3):144.

22. Jelkmann W. Biology of erythropoietin. The Clinical Investigator. 1994 ;72(6 Suppl): S3-10.

23. Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association. 1999 ;14(suppl_2):22-8.

24. Jelkmann W. Regulation of erythropoietin production. The Journal of physiology. 2011;589(6):1251-8.

25. Weiss G, Goodnough LT. Anemia of chronic disease. New England Journal of Medicine. 2005;352(10):1011-23.

26. Yaranal PJ, Umasanah T, Harish SG. Hematological profile in pulmonary tuberculosis. Int J Health Rehabil Sci. 2013;2(1):50.
Impaired in Patients with Hematologic Malignancies.

37. Chaparro CM, Suchdev PS. Anemia epidemiology, pathophysiology, and etiology in low-and middle-income countries. Annals of the New York Academy of Sciences. 2019; 1450(1):15.